147 related articles for article (PubMed ID: 18559593)
1. ssDNA-binding protein 2 is frequently hypermethylated and suppresses cell growth in human prostate cancer.
Liu JW; Nagpal JK; Sun W; Lee J; Kim MS; Ostrow KL; Zhou S; Jeronimo C; Henrique R; Van Criekinge W; Moon CS; Califano JA; Trink B; Sidransky D
Clin Cancer Res; 2008 Jun; 14(12):3754-60. PubMed ID: 18559593
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic regulation of the KAI1 metastasis suppressor gene in human prostate cancer cell lines.
Sekita N; Suzuki H; Ichikawa T; Kito H; Akakura K; Igarashi T; Nakayama T; Watanabe M; Shiraishi T; Toyota M; Yoshie O; Ito H
Jpn J Cancer Res; 2001 Sep; 92(9):947-51. PubMed ID: 11572762
[TBL] [Abstract][Full Text] [Related]
3. Methylation of Integrin α4 and E-Cadherin Genes in Human Prostate Cancer.
Mostafavi-Pour Z; Kianpour S; Dehghani M; Mokarram P; Torabinejad S; Monabati A
Pathol Oncol Res; 2015 Sep; 21(4):921-7. PubMed ID: 25743258
[TBL] [Abstract][Full Text] [Related]
4. Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer.
Henrique R; Costa VL; Cerveira N; Carvalho AL; Hoque MO; Ribeiro FR; Oliveira J; Teixeira MR; Sidransky D; Jerónimo C
J Mol Med (Berl); 2006 Nov; 84(11):911-8. PubMed ID: 17016690
[TBL] [Abstract][Full Text] [Related]
5. Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer.
Ogishima T; Shiina H; Breault JE; Tabatabai L; Bassett WW; Enokida H; Li LC; Kawakami T; Urakami S; Ribeiro-Filho LA; Terashima M; Fujime M; Igawa M; Dahiya R
Clin Cancer Res; 2005 Feb; 11(3):1028-36. PubMed ID: 15709168
[TBL] [Abstract][Full Text] [Related]
6. Promoter hypermethylation of DLC-1, a candidate tumor suppressor gene, in several common human cancers.
Yuan BZ; Durkin ME; Popescu NC
Cancer Genet Cytogenet; 2003 Jan; 140(2):113-7. PubMed ID: 12645648
[TBL] [Abstract][Full Text] [Related]
7. GSTP1 DNA methylation and expression status is indicative of 5-aza-2'-deoxycytidine efficacy in human prostate cancer cells.
Chiam K; Centenera MM; Butler LM; Tilley WD; Bianco-Miotto T
PLoS One; 2011; 6(9):e25634. PubMed ID: 21980513
[TBL] [Abstract][Full Text] [Related]
8. CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer.
Enokida H; Shiina H; Igawa M; Ogishima T; Kawakami T; Bassett WW; Anast JW; Li LC; Urakami S; Terashima M; Verma M; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
Cancer Res; 2004 Sep; 64(17):5956-62. PubMed ID: 15342374
[TBL] [Abstract][Full Text] [Related]
9. Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions.
Henrique R; Jerónimo C; Hoque MO; Carvalho AL; Oliveira J; Teixeira MR; Lopes C; Sidransky D
DNA Cell Biol; 2005 Apr; 24(4):264-9. PubMed ID: 15812243
[TBL] [Abstract][Full Text] [Related]
10. Aberrant methylation of the vascular endothelial growth factor receptor-1 gene in prostate cancer.
Yamada Y; Watanabe M; Yamanaka M; Hirokawa Y; Suzuki H; Takagi A; Matsuzaki T; Sugimura Y; Yatani R; Shiraishi T
Cancer Sci; 2003 Jun; 94(6):536-9. PubMed ID: 12824880
[TBL] [Abstract][Full Text] [Related]
11. Methylation decreases the Bin1 tumor suppressor in ESCC and restoration by decitabine inhibits the epithelial mesenchymal transition.
Wang X; Wang J; Jia Y; Wang Y; Han X; Duan Y; Lv W; Ma M; Liu L
Oncotarget; 2017 Mar; 8(12):19661-19673. PubMed ID: 28152502
[TBL] [Abstract][Full Text] [Related]
12. Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications.
Guan M; Zhou X; Soulitzis N; Spandidos DA; Popescu NC
Clin Cancer Res; 2006 Mar; 12(5):1412-9. PubMed ID: 16533763
[TBL] [Abstract][Full Text] [Related]
13. CpG hypermethylation of the promoter region inactivates the estrogen receptor-beta gene in patients with prostate carcinoma.
Nojima D; Li LC; Dharia A; Perinchery G; Ribeiro-Filho L; Yen TS; Dahiya R
Cancer; 2001 Oct; 92(8):2076-83. PubMed ID: 11596023
[TBL] [Abstract][Full Text] [Related]
14. Hypermethylation of the SPARC promoter and its prognostic value for prostate cancer.
Liu T; Qiu X; Zhao X; Yang R; Lian H; Qu F; Li X; Guo H
Oncol Rep; 2018 Feb; 39(2):659-666. PubMed ID: 29207175
[TBL] [Abstract][Full Text] [Related]
15. Hypoexpression and epigenetic regulation of candidate tumor suppressor gene CADM-2 in human prostate cancer.
Chang G; Xu S; Dhir R; Chandran U; O'Keefe DS; Greenberg NM; Gingrich JR
Clin Cancer Res; 2010 Nov; 16(22):5390-401. PubMed ID: 21062931
[TBL] [Abstract][Full Text] [Related]
16. Quantitative assessment of AKAP12 promoter methylation in colorectal cancer using methylation-sensitive high resolution melting: Correlation with Duke's stage.
Liu W; Guan M; Su B; Ye C; Li J; Zhang X; Liu C; Li M; Lin Y; Lu Y
Cancer Biol Ther; 2010 Jun; 9(11):862-71. PubMed ID: 20364105
[TBL] [Abstract][Full Text] [Related]
17. PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer.
Vanaja DK; Ballman KV; Morlan BW; Cheville JC; Neumann RM; Lieber MM; Tindall DJ; Young CY
Clin Cancer Res; 2006 Feb; 12(4):1128-36. PubMed ID: 16489065
[TBL] [Abstract][Full Text] [Related]
18. MT1G hypermethylation is associated with higher tumor stage in prostate cancer.
Henrique R; Jerónimo C; Hoque MO; Nomoto S; Carvalho AL; Costa VL; Oliveira J; Teixeira MR; Lopes C; Sidransky D
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1274-8. PubMed ID: 15894685
[TBL] [Abstract][Full Text] [Related]
19. Hypermethylation of CpG islands in primary and metastatic human prostate cancer.
Yegnasubramanian S; Kowalski J; Gonzalgo ML; Zahurak M; Piantadosi S; Walsh PC; Bova GS; De Marzo AM; Isaacs WB; Nelson WG
Cancer Res; 2004 Mar; 64(6):1975-86. PubMed ID: 15026333
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic mechanisms of promigratory chemokine CXCL14 regulation in human prostate cancer cells.
Song EY; Shurin MR; Tourkova IL; Gutkin DW; Shurin GV
Cancer Res; 2010 Jun; 70(11):4394-401. PubMed ID: 20460540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
